Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:32PM ET
51.86
Dollar change
+0.70
Percentage change
1.37
%
Index- P/E11.44 EPS (ttm)4.53 Insider Own0.04% Shs Outstand1.22B Perf Week2.69%
Market Cap63.38B Forward P/E9.96 EPS next Y5.21 Insider Trans0.00% Shs Float1.22B Perf Month8.08%
Income5.51B PEG1.82 EPS next Q1.15 Inst Own47.30% Short Float1.82% Perf Quarter7.17%
Sales53.56B P/S1.18 EPS this Y0.28% Inst Trans7.68% Short Ratio10.82 Perf Half Y13.85%
Book/sh42.86 P/B1.21 EPS next Y7.83% ROA0.56% Short Interest22.29M Perf Year5.77%
Cash/sh- P/C- EPS next 5Y6.30% ROE10.16% 52W Range39.79 - 51.80 Perf YTD6.51%
Dividend Est.3.17 (6.11%) P/FCF4.68 EPS past 5Y-4.16% ROI5.90% 52W High0.11% Beta1.02
Dividend TTM3.14 (6.06%) Quick Ratio- Sales past 5Y12.04% Gross Margin- 52W Low30.31% ATR (14)0.67
Dividend Ex-DateApr 01, 2024 Current Ratio0.66 EPS Y/Y TTM-17.94% Oper. Margin11.79% RSI (14)73.28 Volatility1.01% 1.22%
Employees89483 Debt/Eq2.80 Sales Y/Y TTM33.57% Profit Margin10.28% Recom3.14 Target Price50.41
Option/ShortYes / Yes LT Debt/Eq0.58 EPS Q/Q23.45% Payout71.57% Rel Volume2.21 Prev Close51.16
Sales Surprise2.30% EPS Surprise4.83% Sales Q/Q14.23% EarningsFeb 27 BMO Avg Volume2.06M Price51.86
SMA203.99% SMA508.05% SMA20010.87% Trades Volume4,230,522 Change1.37%
Date Action Analyst Rating Change Price Target Change
Mar-20-24Initiated Barclays Underweight
Feb-22-24Initiated Jefferies Hold
May-09-23Downgrade Barclays Equal Weight → Underweight
Mar-01-23Downgrade Canaccord Genuity Buy → Hold
Aug-24-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-22Downgrade Keefe Bruyette Outperform → Mkt Perform
Aug-24-22Downgrade BMO Capital Markets Outperform → Market Perform $95
May-20-22Resumed Credit Suisse Neutral
Apr-11-22Downgrade CIBC Sector Outperform → Neutral
Mar-10-22Downgrade TD Securities Buy → Hold
Today 12:50PM
Mar-27-24 03:55AM
Mar-26-24 01:30PM
Mar-22-24 09:00AM
Mar-20-24 09:00AM
09:00AM Loading…
Mar-18-24 09:00AM
07:00AM
Mar-15-24 08:51AM
Mar-14-24 09:41AM
Mar-11-24 10:01AM
Mar-10-24 08:15AM
08:12AM
Mar-07-24 09:39AM
Mar-06-24 12:16PM
10:52AM
08:08AM Loading…
Mar-04-24 08:08AM
Mar-03-24 08:21AM
08:16AM
Mar-01-24 10:09AM
10:07AM
Feb-29-24 02:12PM
11:39AM
08:10AM
Feb-28-24 09:01AM
09:00AM
09:00AM
Feb-27-24 02:17PM
02:05PM
12:16PM
08:50AM
07:50AM Loading…
07:50AM
05:51AM
05:35AM
05:34AM
05:30AM
Feb-23-24 09:20AM
08:05AM
08:00AM
Feb-22-24 06:00AM
Feb-20-24 10:00AM
09:00AM
Feb-16-24 09:00AM
Feb-14-24 07:41AM
07:39AM
07:30AM
Feb-13-24 07:00AM
Feb-09-24 02:00PM
Feb-02-24 09:00AM
Feb-01-24 09:00AM
Jan-31-24 07:00AM
Jan-28-24 11:39AM
Jan-25-24 06:44AM
Jan-24-24 12:12PM
Jan-19-24 09:00AM
Jan-13-24 02:38PM
Jan-04-24 05:35AM
Jan-02-24 09:00AM
Jan-01-24 11:02AM
Dec-28-23 09:00AM
09:00AM
Dec-23-23 07:00AM
Dec-20-23 09:00AM
09:00AM
Dec-18-23 12:19PM
09:56AM
09:49AM
Dec-15-23 10:45AM
Dec-14-23 02:37PM
02:30PM
09:30AM
Dec-13-23 04:14PM
Dec-11-23 04:17PM
06:33AM
06:00AM
Dec-08-23 05:00PM
Dec-05-23 09:34AM
Dec-01-23 10:07AM
09:00AM
Nov-30-23 12:35PM
Nov-29-23 03:58PM
11:20AM
09:00AM
09:00AM
05:42AM
Nov-28-23 05:49PM
04:46PM
04:17PM
03:22PM
01:31PM
10:07AM
09:45AM
07:26AM
06:28AM
06:15AM
06:05AM
06:02AM
06:00AM
Nov-27-23 05:00PM
Nov-24-23 08:00AM
Nov-21-23 10:00AM
The Bank of Nova Scotia engages in the provision of financial products and services including personal, commercial, corporate, and investment banking. It operates through the following segments: Canadian Banking, International Banking, Global Wealth Management, Global Banking and Markets, and Other. The Other segment includes group treasury and smaller operating segments. The company was founded on March 30, 1832 and is headquartered in Toronto, Canada.
Last Close
Mar 28 03:31PM ET
129.70
Dollar change
-0.53
Percentage change
-0.41
%
SRPT Sarepta Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-6.16 Insider Own5.98% Shs Outstand93.73M Perf Week3.81%
Market Cap12.17B Forward P/E11.47 EPS next Y11.31 Insider Trans0.92% Shs Float88.24M Perf Month-5.68%
Income-535.98M PEG- EPS next Q-0.03 Inst Own86.86% Short Float5.63% Perf Quarter33.93%
Sales1.24B P/S9.79 EPS this Y143.14% Inst Trans6.40% Short Ratio4.61 Perf Half Y5.07%
Book/sh9.17 P/B14.15 EPS next Y351.90% ROA-16.77% Short Interest4.97M Perf Year-1.10%
Cash/sh17.86 P/C7.26 EPS next 5Y- ROE-86.15% 52W Range55.25 - 159.89 Perf YTD34.50%
Dividend Est.- P/FCF- EPS past 5Y-1.21% ROI-25.13% 52W High-18.88% Beta0.94
Dividend TTM- Quick Ratio3.45 Sales past 5Y32.89% Gross Margin84.34% 52W Low134.74% ATR (14)3.77
Dividend Ex-Date- Current Ratio3.95 EPS Y/Y TTM24.04% Oper. Margin-21.54% RSI (14)58.58 Volatility2.46% 3.26%
Employees1314 Debt/Eq1.63 Sales Y/Y TTM33.26% Profit Margin-43.11% Recom1.43 Target Price164.33
Option/ShortYes / Yes LT Debt/Eq1.48 EPS Q/Q134.77% Payout- Rel Volume0.32 Prev Close130.23
Sales Surprise2.48% EPS Surprise582.15% Sales Q/Q53.54% EarningsFeb 28 AMC Avg Volume1.08M Price129.70
SMA204.00% SMA503.40% SMA20016.80% Trades Volume322,418 Change-0.41%
Date Action Analyst Rating Change Price Target Change
Jan-31-24Initiated BMO Capital Markets Outperform $170
Dec-13-23Resumed Citigroup Buy $113
Dec-12-23Initiated Deutsche Bank Buy $109
Nov-21-23Initiated Wedbush Outperform $224
Oct-31-23Downgrade Oppenheimer Outperform → Perform
Oct-31-23Downgrade Cantor Fitzgerald Overweight → Neutral $166 → $40
Jun-23-23Downgrade Evercore ISI Outperform → In-line $139
Apr-26-23Initiated SMBC Nikko Outperform $185
Apr-04-23Initiated Citigroup Buy $179
Mar-01-23Upgrade Morgan Stanley Equal-Weight → Overweight $141 → $187
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
01:18AM Loading…
Mar-12-24 01:18AM
Mar-11-24 09:03AM
Mar-06-24 11:54PM
Mar-04-24 09:47AM
08:30AM
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM Loading…
12:00AM
Feb-28-24 06:00PM
04:23PM
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
08:30AM
Feb-20-24 10:00AM
Feb-19-24 03:26AM
Feb-16-24 11:23AM
11:22AM
08:46AM
07:41AM
07:22AM
07:00AM Loading…
07:00AM
Feb-15-24 07:45AM
Feb-11-24 01:45AM
Jan-31-24 06:29PM
Jan-29-24 07:37AM
07:12AM
07:00AM
06:50AM
Jan-26-24 05:15AM
Jan-25-24 09:45AM
Jan-22-24 05:47PM
09:55AM
09:38AM
Jan-16-24 03:57PM
09:02AM
Jan-10-24 11:43AM
06:17AM
Jan-09-24 11:22AM
10:52AM
07:15AM
Jan-08-24 11:55AM
Jan-04-24 09:55AM
Jan-02-24 08:30AM
Dec-29-23 06:27PM
08:44AM
Dec-28-23 10:07AM
Dec-27-23 06:26PM
Dec-26-23 06:56PM
Dec-22-23 02:49PM
10:15AM
08:00AM
06:33AM
Dec-17-23 09:45AM
Dec-15-23 09:55AM
Dec-12-23 12:43PM
Dec-09-23 07:00AM
Dec-01-23 11:31AM
Nov-30-23 06:34PM
Nov-29-23 09:55AM
Nov-27-23 09:50AM
Nov-24-23 10:26AM
Nov-18-23 06:49AM
Nov-16-23 06:35AM
Nov-13-23 09:55AM
07:57AM
Nov-10-23 12:58AM
Nov-09-23 10:00AM
Nov-08-23 10:15AM
Nov-07-23 11:23PM
Nov-02-23 06:25PM
12:18PM
08:30AM
12:00AM
Nov-01-23 05:03PM
04:29PM
04:05PM
Oct-31-23 07:02PM
04:19PM
04:07PM
03:03PM
11:52AM
10:26AM
10:21AM
09:38AM
09:19AM
08:01AM
07:51AM
07:19AM
Oct-30-23 04:28PM
04:10PM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boor Kathryn JeanDirectorMar 11 '24Sale122.9376193,5507,516Mar 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Option Exercise13.9015,000208,50037,840Mar 11 08:02 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Sale123.2515,0001,848,79522,840Mar 11 08:02 PM
Mayo StephenDirectorMar 05 '24Sale122.963,135385,4806,621Mar 06 08:00 PM
Arif BilalChief Tech Ops OfficerMar 01 '24Sale128.842,000257,67626,836Mar 05 08:00 PM
Brown Ryan EdwardEVP, General CounselMar 01 '24Sale125.342,000250,68031,827Mar 05 08:00 PM
Estepan Ian MichaelChief Financial OfficerMar 01 '24Sale128.301,200153,96039,114Mar 05 08:00 PM
BEHRENS M KATHLEENDirectorNov 03 '23Option Exercise29.0315,000435,450174,993Nov 06 08:00 AM
Barry RichardDirectorNov 03 '23Buy78.8150,0003,940,500140,000Nov 06 08:00 AM
INGRAM DOUGLAS SPresident & CEONov 03 '23Buy79.3625,2252,001,800390,307Nov 06 08:00 AM
Chambers Michael AndrewDirectorAug 14 '23Buy109.479,9791,092,429246,996Aug 15 08:00 AM
Chambers Michael AndrewDirectorAug 11 '23Buy108.0523,6862,559,272237,017Aug 14 08:00 AM
Chambers Michael AndrewDirectorAug 10 '23Buy106.1534,8673,701,067213,331Aug 11 07:40 AM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Option Exercise29.0315,000435,45035,994Aug 08 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Sale106.7215,0001,600,80020,994Aug 08 08:00 PM